Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by alejo.g3ologiston Jul 21, 2019 4:57pm
52 Views
Post# 29944390

RE:RE:RE:RE:RE:RE:RE:RE:DO INSIDERS OWN REAL SHARES??

RE:RE:RE:RE:RE:RE:RE:RE:DO INSIDERS OWN REAL SHARES??
cr7epl wrote:  stressed  fock no lol go look at those plays, just ticked at this one as i think the pumpers got  to me, dont normally buy anything i cant have some  kind acess to the ceo and pic his head .......pumpers had this for quote  "easy double" lol and its 035 and the L2 evryday is like 8 million away from 08 so where this  one goof ball  on here thinks its 065 in weeks ??  Man do these guys ever look at the L2 daily ??  i dont think so! PP  can drive a guy nuts LOL  but aleast he  claims to have called kaly which is 99%  more then most clowns do,  so you cant fault him for that and his info!!


yeh if u are looking for an easy doble, short term investment you are at the wrong spot. also if you are just swing trading would not recommend this neither. level 2 is posted 5 times a day on the facebook group im part of. and its up to u who u believe in..if penny is ur source guy then go for it!
wonder urself why a normal individual would post 100 times a day on here same thing over and over? thats alarming from a phycological perspective..not even a paid troll would be that annoying.
kly will partner up with a big pharma/cannabis company, mark my words! thats all, whether shareholders get a piece of the cake thats a different story, it all depends how well positioned one is average wise...  
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities